US 10,370,670 B2Granted

Double-stranded ribonucleic acid for adjuvants

AssigneeKyowa Hakko Bio Co., Ltd.

InventorsTetsuo Nakano, Eitora Yamamura

Life of this patent

Estimating the term…

Loading patent…

Abstract

The invention provides a double-stranded ribonucleic acid (dsRNA) having a chain length suitable for simultaneously showing low toxicity and high function in the use of an adjuvant and the like, and resisting variation of chain length even when subjected to a heating and cooling treatment, or a salt thereof; an immune potentiator, adjuvant, pharmaceutical product and the like containing the dsRNA and the like; and a production method of such dsRNA and the like. The invention is characterized in that the weight average chain length of two or more single-stranded ribonucleic acids (ssRNAs) constituting the first chain constituting dsRNA is not more than ½ of the weight average chain length of one ssRNA constituting the second chain.

Claims1

Dependent claims

A double-stranded ribonucleic acid (dsRNA) having a weight average chain length within the range of 0.2 kilobase pairs (kbp) to 0.6 kbp, or a salt thereof, wherein

the first chain of the dsRNA consists of two or more polyinosinic acids having a weight average chain length of 0.1-0.2 kilobase (kb),
the second chain of the dsRNA consists of one single-stranded ribonucleic acid (ssRNA) having a weight average chain length of 0.3-0.4 kb, which contains cytidylic acid at a rate of not less than 80%,
the dsRNA has a median value of 0.1-0.35 kbp, and
the weight average chain length of the two or more polyinosinic acids constituting the first chain is not more than ½ of the weight average chain length of one ssRNA which contains cytidylic acid at a ratio of not less than 80% constituting the second chain.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 15/791,742Filed 24 Oct 2017 · division
Priority: JP 2012-2670126 Dec 2012
Published: US 2018/0044678 A115 Feb 2018
Granted: 6 Aug 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification13 codes

C12N 15/117
DNA or RNA fragments; Modified forms thereof ; Non-coding nucleic acids having a biological activity: nucleic acids having immunomodulatory…
A61K 31/713
Compounds having three or more nucleosides or nucleotides: double-stranded nucleic acids or oligonucleotides
A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61P 37/04
Immunomodulators: immunostimulants

Family

PCT/JP2013/082774Parent of this division · filed 6 Dec 2013
US 2018/0044678 A1Pre-grant publication · published 15 Feb 2018
Application14/650,229Parent of this division
US 9,816,095 B2Parent of this division
US 2015/0307884 A1Published application
US 10,370,670 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key